Max Robotics — Global Service Robot Directory + US Certification

About

Kathleen T. Montone is a leading head and neck pathologist whose research has fundamentally shaped the management of oropharyngeal cancer, particularly in the era of human papillomavirus (HPV)-related disease. Her key contributions center on refining surgical and adjuvant treatment strategies to maximize oncologic control while minimizing treatment morbidity. Montone’s landmark 2012 study on transoral robotic surgery (TORS) alone for oropharyngeal squamous cell carcinoma (228 citations) established a paradigm for single-modality treatment, demonstrating excellent local control. She further advanced de-escalation protocols with the AVOID trial (167 citations), which showed that omitting radiation to the resected primary tumor bed after TORS is safe for HPV-positive patients. Her work on occult primary detection (69 citations) provided a diagnostic framework using TORS-assisted endoscopy, reducing the need for extensive mucosal irradiation. Montone also investigated the prognostic role of p16INK4a immunohistochemistry (45 citations), helping to stratify patients by risk. Her recent benchmark study (2022) models lethal recurrence risk in HPV-related cancers, offering a tool for personalized surveillance. Through these contributions, Montone has been instrumental in moving the field toward less toxic, more precise therapies for head and neck cancer patients.